A Phase 2 proof-of-concept trial of SB414 as a topical treatment in patients with mild-to-moderate psoriasis

Trial Profile

A Phase 2 proof-of-concept trial of SB414 as a topical treatment in patients with mild-to-moderate psoriasis

Planning
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs SB 414 (Primary)
  • Indications Psoriasis
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 05 Jun 2017 According to a Novan Inc media release, the company anticipates to initiate this study in the third quarter of 2017.
    • 12 May 2017 According to a Novan Inc media release, the company plans to submit an Investigational New Drug application to the U.S. Food and Drug Administration later this quarter for the initiation of this study.
    • 20 Mar 2017 According to a Novan Inc media release, company expects to initiate clinical development of SB414 following an IND submission in the second quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top